ANTIVIRAL THERAPY
Scope & Guideline
Exploring innovative therapies for viral infections.
Introduction
Aims and Scopes
- Antiviral Drug Development:
Research on new antiviral agents, including their mechanisms of action, efficacy, and safety profiles. - Clinical Trials and Observational Studies:
Investigation of antiviral therapies through controlled trials, real-world studies, and retrospective analyses to assess treatment outcomes. - Resistance Mechanisms:
Studies focused on understanding viral resistance to antiviral medications, including genotypic and phenotypic analyses. - Co-infection Studies:
Exploration of the interactions and treatment implications of co-infections, particularly between HIV, hepatitis viruses, and other pathogens. - Public Health and Epidemiology:
Research addressing the epidemiology of viral infections and the impact of antiviral therapies on public health outcomes. - Innovative Therapeutic Approaches:
Development and assessment of novel treatment strategies, including combination therapies, long-acting formulations, and personalized medicine.
Trending and Emerging
- COVID-19 and Post-Acute Sequelae:
An increasing number of studies are addressing the impact of COVID-19, including treatment approaches and the long-term effects of the virus on various populations. - Monoclonal Antibody Therapies:
Research focusing on the use of monoclonal antibodies in treating viral infections, particularly COVID-19 and other emerging viruses, is gaining traction. - HIV Treatment Innovations:
There is a growing focus on novel treatment regimens, including long-acting injectables and dual therapy approaches, reflecting ongoing advancements in HIV care. - Mechanistic Studies of Viral Pathogenesis:
Studies elucidating the mechanisms by which viruses evade immune responses and develop resistance are increasingly prominent, particularly in relation to emerging viruses. - Integrated Care Models for Co-infections:
Research on integrated care approaches for managing co-infections, particularly among vulnerable populations, is becoming more common as co-morbidities are recognized as critical factors in treatment.
Declining or Waning
- Traditional Antiviral Agents:
Research on older antiviral agents, such as acyclovir or older nucleoside analogs, has decreased as newer therapies and mechanisms gain prominence. - Vaccine Development:
While still relevant, the volume of publications specifically focused on vaccine development against viral infections has waned compared to other therapeutic strategies. - HIV/AIDS Related Stigma Studies:
Research examining the social stigma related to HIV/AIDS treatment and care has become less frequent, possibly due to a broader focus on clinical outcomes and therapy effectiveness. - Longitudinal Studies in Stable Populations:
Long-term studies examining stable populations with established treatment regimens have decreased, as the focus shifts to dynamic clinical settings and emerging therapies.
Similar Journals
Advances in Virology
Exploring the Frontiers of Infectious DiseasesAdvances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.
Journal of Virus Eradication
Pioneering discoveries in virology and public health.Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.
CHEMOTHERAPY
Advancing the Frontiers of Chemotherapy ResearchCHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.
INVESTIGATIONAL NEW DRUGS
Unlocking Potential: Transforming Drug ResearchINVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.
Viral Hepatit Dergisi-Viral Hepatitis Journal
Uniting experts to combat viral hepatitis.Viral Hepatit Dergisi - Viral Hepatitis Journal, published by GALENOS PUBL HOUSE, is a preeminent journal dedicated to advancing the field of viral hepatitis research. With an ISSN of 1307-9441 and an E-ISSN of 2147-2939, it serves as a vital platform for the dissemination of cutting-edge studies and clinical findings related to the prevention, diagnosis, and treatment of viral hepatitis. The journal aims to foster collaboration among researchers, medical professionals, and students by providing open access to high-quality research articles and reviews. Although specific impact metrics such as H-Index are not detailed, the journal is well-regarded in its field, contributing significantly to the understanding of viral hepatitis and its global implications. Positioned in Istanbul, Turkey, it draws upon a rich academic tradition, ensuring comprehensive coverage of the subject. This journal is indispensable for anyone invested in the fight against viral hepatitis, enriching the scholarly literature while promoting informed practices in healthcare.
INTERVIROLOGY
Uncovering breakthroughs in virology and infectious diseases.INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.
Infectious Diseases and Therapy
Elevating research to combat infectious diseases worldwide.Infectious Diseases and Therapy is a premier scholarly journal published by Springer London Ltd, dedicated to advancing the understanding of infectious diseases through rigorous research and evidence-based therapy. With an esteemed Q1 ranking in both the Infectious Diseases and Microbiology (medical) categories, this journal is a vital resource for researchers, healthcare professionals, and students aiming to stay at the forefront of developments within the field. Launched in 2012, it has embraced an Open Access model, ensuring that groundbreaking studies and critical reviews are accessible to a global audience. Operating from its office in London, the journal encourages the dissemination of innovative therapies and diagnostic methods, fostering collaboration and knowledge sharing among the scientific community. In a landscape where infectious diseases pose significant health challenges, Infectious Diseases and Therapy stands as an essential platform for impactful research that can lead to improved healthcare outcomes worldwide.
JOURNAL DE MYCOLOGIE MEDICALE
Innovating Research for Infectious Disease SolutionsJOURNAL DE MYCOLOGIE MEDICALE is a premier publication in the field of infectious diseases, particularly focusing on the study of mycology and its clinical implications. Published by MASSON EDITEUR, this esteemed journal is based in France and has been disseminating valuable research since its inception in 1994. With an ISSN of 1156-5233 and an E-ISSN of 1773-0449, it plays a critical role in advancing knowledge in mycological infections, positioning itself in the Q3 category for infectious diseases as per the 2023 quartiles. As indicated by its ranking in Scopus, ranking #142 out of 344 in the medicine-infectious diseases category, the journal maintains a prominent presence within the academic community, appealing to researchers, healthcare professionals, and students alike. Although access options are not open access, the journal endeavors to promote a deeper understanding of mycological studies that are crucial for combating ongoing and emerging infectious threats. As it continues to converge on new findings up to 2024, JOURNAL DE MYCOLOGIE MEDICALE remains an essential resource for those invested in the critical intersections of mycology and medicine.
ARCHIVES OF VIROLOGY
Elevating the discourse on viral health impacts.Archives of Virology is a prestigious academic journal dedicated to the field of virology, published by Springer Wien. Established in 1975, this journal has been a crucial platform for disseminating innovative research findings and advancements in the understanding of viral diseases and their impact on human health. It holds a notable position in the academic landscape, with a 2023 impact factor placing it in Q2 within the field of Medicine (miscellaneous) and Q3 in Virology. Its Scopus ranking within the Virology category further underscores its relevance, with a notable percentile of 45th. Although it does not provide Open Access options, the journal's rigorous peer-review process ensures the highest quality of published work, making it an essential resource for researchers, professionals, and students aiming to stay updated in the rapidly evolving field of virology. For those committed to advancing their understanding of viruses and viral diseases, Archives of Virology is a vital scholarly resource.
Annual Review of Virology
Your essential resource for cutting-edge virology reviews.Annual Review of Virology is a premier scholarly journal published by Annual Reviews, dedicated to advancing the field of virology through comprehensive and insightful reviews. Since its inception in 2014, this journal has established itself as a leading resource for researchers, professionals, and students alike, achieving an impressive Q1 ranking in the field of Virology and a Scopus rank of #10 out of 80 in its category, placing it in the 88th percentile. The journal features in-depth analyses of the latest developments in virology, encompassing various aspects such as viral pathogenesis, host interactions, and antiviral strategies, thereby catering to a diverse audience seeking the most relevant and cutting-edge information. Although it is not Open Access, Annual Review of Virology remains an indispensable tool for those engaged in virology research, transforming complex findings into accessible knowledge that shapes future investigations and practical applications in the field.